NCT01061411 is a Phase 1 clinical trial of Dalteparin in Clear Cell Sarcoma of the Kidney, sponsored by Roswell Park Cancer Institute.

Who is sponsoring NCT01061411?

NCT01061411 is sponsored by Roswell Park Cancer Institute.

What drugs are being tested in NCT01061411?

Interventions in NCT01061411: Dalteparin, Pharmacological Study, Sunitinib Malate.

What condition does NCT01061411 study?

NCT01061411 studies Clear Cell Sarcoma of the Kidney, Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer.

Is NCT01061411 still recruiting?

NCT01061411 is currently completed. Last updated 5 August 2022.

Last reviewed 2022-08-05 · How we verify

NCT01061411

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery

Completed Phase 1 Last updated 5 August 2022

What this trial tests

Phase 1 trial testing Dalteparin in Clear Cell Sarcoma of the Kidney in 16 participants. Completed in 21 April 2017.

Timeline

6 February 2010

Primary endpoint
14 October 2015

21 April 2017

Quick facts

Lead sponsor	Roswell Park Cancer Institute
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	16
Start date	6 February 2010
Primary completion	14 October 2015
Estimated completion	21 April 2017
Sites	4 locations across Netherlands, United States

Drugs / interventions tested

Dalteparin
Pharmacological Study — full drug profile →
Sunitinib Malate (sunitinib-malate) — full drug profile →

Conditions studied

Clear Cell Sarcoma of the Kidney — all drugs for Clear Cell Sarcoma of the Kidney →
Recurrent Renal Cell Carcinoma — all drugs for Recurrent Renal Cell Carcinoma →
Stage III Renal Cell Cancer — all drugs for Stage III Renal Cell Cancer →
Stage IV Renal Cell Cancer — all drugs for Stage IV Renal Cell Cancer →

Sponsor

Roswell Park Cancer Institute

Who can join

18 and older, any sex, with Clear Cell Sarcoma of the Kidney or Recurrent Renal Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase I trial studies the side effects and best dose of dalteparin when given together with sunitinib malate in treating patients with kidney cancer that has spread to other parts of the body or cannot be removed by surgery. Anticoagulants, such as dalteparin, help prevent blood clots and have been shown to increase survival in patients with cancer. Anticoagulants may also prevent the formation of new blood vessels. Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by inhibiting new blood vessels and blocking blood flow to the tumor. Giving dalteparin together with sunitinib malate may starve tumors and kill more tumor cells.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Thromboprophylaxis guidelines in cancer with a primary focus on ambulatory patients receiving chemotherapy: a review from the Southern Network on Adverse Reactions (SONAR).
Maxwell WD, Bennett CL. · · 2012 · cited 9× · PMID 23111863 · DOI 10.1055/s-0032-1328893

Verify or expand the search:

Other trials of Dalteparin

Trials testing the same drug.

NCT06628778 — Collaborative Risk-stratified Investigation in Teen Inpatients With Critical Illness: Anticoagulation With LMWH in Kids · Phase 3 · not yet recruiting
NCT05171075 — A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE · Phase 3 · terminated
NCT04850378 — Causes and Prevention of Thromboembolic Disease in Nephrotic Syndrome · Phase 1, PHASE2 · completed
NCT03297359 — WAVe Study - Weight Adjusted Dalteparin for Patients Over 90 kg With Acute Cancer Associated Venous Thromboembolism · Phase 2 · terminated
NCT03139487 — A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral · Phase 2 · unknown

Other recruiting trials for Clear Cell Sarcoma of the Kidney

Currently open trials in the same condition.

NCT00898365 — Study of Kidney Tumors in Younger Patients · active not recruiting

Other Roswell Park Cancer Institute trials

Trials by the same sponsor.

NCT07489287 — GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer · Phase 1 · not yet recruiting
NCT06943664 — Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-I · Phase 2 · not yet recruiting
NCT06827054 — Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids · Phase 2 · not yet recruiting
NCT06334016 — Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream · EARLY_PHASE1 · not yet recruiting
NCT06670976 — Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarcoma · Phase 1 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01061411 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Roswell Park Cancer Institute
Last refreshed: 5 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01061411.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing